Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Brasschaat – page 2

63 clinical trials in Brasschaat, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Brasschaat at a glance
63
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

63 trials in Brasschaat

Open in trial search

Myelodysplastic syndrome

Recruiting

Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Ascentage Pharma Group Inc.

Small cell lung cancer limited stage

Recruiting

Study on Toripalimab and Tifcemalimab for Patients with Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tifcemalimab
  • Sponsor:Shanghai Junshi Biosciences Co. Ltd.

Squamous cell carcinoma of lung+2

Recruiting

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Hormone receptor positive HER2 negative breast cancer

Recruiting

Study on Elacestrant for Treating ER+/HER2- Breast Cancer in Patients with ctDNA Relapse

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Non-small cell lung cancer

Recruiting

Study Comparing Telisotuzumab Vedotin and Docetaxel for Adults with Previously Treated Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Recruiting

Study on Preventing Crohn's Disease Recurrence After Surgery Using Risankizumab and Drug Combination in Adults at Risk

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:UZ Leuven

Neuroendocrine tumour+2

Recruiting

Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Antwerp University Hospital

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Recruiting
Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Triple negative breast cancer

Recruiting

Study of Sacituzumab Govitecan and Pembrolizumab for Patients with Triple Negative Breast Cancer with Residual Disease After Surgery and Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Gilead Sciences Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:Eli Lilly & Co.

Diffuse large B-cell lymphoma

Not yet recruiting

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Brasschaat

What the registry says about research in the country

01 Oncology Research

Groundbreaking clinical trials focusing on lung cancer treatments, including studies of novel therapies for both non-small cell and small cell lung cancer. Several trials are evaluating innovative combination therapies and targeted treatments for patients with specific genetic markers.

  • Non-small cell lung cancer therapies
  • Small cell lung cancer treatments
  • Targeted molecular therapies
02 Breast Cancer Studies

Multiple trials investigating new treatments for breast cancer, particularly focusing on hormone receptor-positive and HER2-negative subtypes. Research includes evaluation of novel therapeutic approaches and comparative studies of different treatment regimens.

  • Early-stage breast cancer
  • Hormone receptor-positive disease
  • Triple-negative breast cancer
03 Hematological Research

Comprehensive studies in multiple myeloma and other blood disorders, investigating new therapeutic options and treatment combinations. Trials include evaluation of novel agents for both newly diagnosed and relapsed/refractory cases.

  • Multiple myeloma treatments
  • Myelodysplastic syndromes
  • Immune thrombocytopenia
Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.